Quantcast

Latest Docetaxel Stories

2011-12-08 12:55:30

Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from an investigator assessment that the improvement was present but statistically non-significant. Luca Gianni, M.D., director of medical oncology at the San Raffaele Cancer Center in Milano, Italy, presented results from AVEREL, a randomized, phase 3 trial, at the 2011...

2011-12-08 12:53:09

Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo. Researchers conducted an international phase 3, double-blind, randomized trial, known as CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab), in which they randomly assigned 808 patients to receive trastuzumab and...

2011-09-26 11:11:04

The first randomized trial to investigate the use of trastuzumab emtansine (T-DM1) — an antibody-guided drug — for the initial treatment of HER2- (human epidermal growth factor receptor-2) positive metastatic breast cancer has shown that it makes a significant difference to the time women live without their disease worsening. Dr Sara Hurvitz, one of the trial investigators, will tell the 2011 European Multidisciplinary Cancer Congress in Stockholm today (Sunday 25 September):...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'